Risk analysis for products in development
RAPID studies the health effects of exposure to hazardous substances in the workplace, in the environment, and after intake. It develops innovative approaches for early prediction of health effects resulting from such exposure, as well as measuring, modelling, and managing exposure. We do this research within national and international legal frameworks, and we focus on earlier process phases, such as the development of new ingredients, materials, and products by means of Safe and Sustainable by Design concepts.
Health risks of hazardous substances
On the basis of RAPID, we’re increasingly modelling health risks of hazardous substances for humans in order to reduce costs and increase speed. In doing so, we combine in-depth knowledge of risk analysis and statistics with practical experience in the field of innovative experimental research. This includes research into toxicology, immune health, epidemiology, chemistry, human exposure, statistics, and modelling. For example, we’re developing integrated strategies that predict human health risks with high precision and make minimal use of animal studies.
We use the Diamonds data platform to integrate data for Life Sciences in various domains, such as risk assessments of substances, safety assessments of drug targets, and decision support systems for personalised advice.
The focus of RAPID is to demonstrate whether innovations work to a sufficient degree (proof of principle), and to deliver a first application, in which the working principle is used (proof of market). With external partners, we shape the further upscaling of a significant part of these innovations in the private market.
We’re strongly internationally oriented and focus on industrial challenges within three business sectors:
We also support governments with their research issues.
Applications and impact
Some examples of our applications with their impact on society:
- Based on research among a large number of industry organisations, we conclude that many Dutch citizens may be exposed to nanoparticles in the workplace. These results serve as a basis for new large-scale research into nanoparticle exposure among Dutch workers.
- We’ve shown that the concentration of allergens in foodstuffs can cause public health risks through cross-contamination. A model we developed calculates the number of consumers who have an allergic reaction to a certain concentration of an allergen in food. Our research and the international database managed by TNO, with more than 3500 sensitivity thresholds in individual patients with food allergies, form the basis for WHO/FAO advice on safe limits for allergens in food.
- RAPID plays a leading role in developing the multidisciplinary exposome paradigm. The exposome identifies multifactorial health stressors, resulting from multiple and lifelong exposure, in relation to health effects. The exposome is taking on an increasingly significant role in determining/measuring health and developing strategies for health interventions.
- RAPID has developed a digital text-mining application called Target Tri to help pharmaceutical companies with the early selection of new drug targets. Target Tri can quickly establish the safety and effectiveness of targets.
Connecting the dots for effective disease prevention
Read our white paper on how environmental exposures are a major risk factor for disease.
Carina de Jong-RubinghFunctie:Research Manager
Carina de Jong is Research Manager from the research group Risk Analysis for Products In Development (RAPID). Within RAPID we develop and apply innovative health assessments for substances to improve healthy living and work.
Telefoon:+31 6 15 48 70 05
LinkedIn:Carina on LinkedIn
Looking for an expert?View all experts
Ancora Health develops personal diabetes plan with 360 methodology
With the help of TNO's knowledge of diabetic typing, Ancora Health wants to implement a diabetes lifestyle programme within healthcare.
MixMasters uses TNO phenotype test to offer personalised nutrition
TNO is helping MixMasters answer the question 'How can we personalise while remaining user-friendly?' Moreover, during their collaboration, the idea for a new concept was born: FoodiYou.
Personalised Health: Take it personal
TNO helps companies develop scientifically based personalised health applications. Knowledge is translated into applications by using a systems approach, and personalised health is put into practice. An example of this is the collaboration with Gabriele Ronnett of Johnson & Johnson Consumer Health Company.
Personalised Health: From science to market
Are you interested in developing personalised health in order to contribute to a healthier society? Get inspired by the experience of companies that already innovate with us. Watch this interactive webinar for the latest insights in personalised health: from science to market.
TNO publishes fully integreated Annual Report 2022
TNO's Annual Report 2022 is published. For the first time, it concerns a fully integrated annual report, in which sustainability is fully incorporated into the general annual report.